CSL Behring clinical trials

Acquired by CSL Limited, Mar 31, 2004 · source ↗

The registry lists 145 studies whose lead sponsor is CSL Behring. 17 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 145. List all 145 → · All CSL Limited studies →

• Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BRecruitingNCT07080905Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)RecruitingNCT07048262Phase 2

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)RecruitingNCT07326592Phase 4

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)RecruitingNCT07094087Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesRecruitingNCT07648264Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive SurgeryRecruitingNCT06617897Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 StudyAvailableNCT07159464

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive CrisisRecruitingNCT06699849Phase 2

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)RecruitingNCT05485961Phase 2/3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)RecruitingNCT06003387Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)RecruitingNCT07224360Phase 2

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)RecruitingNCT07619820Phase 1

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)RecruitingNCT07001280

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Two Dose Levels of Privigen in Pediatric CIDPRecruitingNCT03684018Phase 4

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BRecruitingNCT06008938

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)Enrolling by invitationNCT05962398

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Hizentra® in Inflammatory Neuropathies - pHeNIx StudyRecruitingNCT04672733

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary HemochromatosisActive, not recruitingNCT07332091Phase 2

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell TransplantTerminatedNCT03805789Phase 2/3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids AloneCompletedNCT04167514Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX TherapyCompletedNCT06399289Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to GaradacimabCompletedNCT06806657Phase 4

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CompletedNCT07076446Phase 4

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary AngioedemaCompletedNCT05819775Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema AttacksCompletedNCT04739059Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia BCompletedNCT05360706

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTSTerminatedNCT06524739Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B PatientsCompletedNCT03569891Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy SubjectsCompletedNCT05937581Phase 1

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )TerminatedNCT05568888Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)TerminatedNCT04044690Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy AdultsCompletedNCT06996184Phase 1

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant RecipientsTerminatedNCT03744910Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy AdultsCompletedNCT06726863Phase 1

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Respreeza® Self-administration and Learning Program (AmAREtTI Study)CompletedNCT04262284

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Study to Investigate CSL112 in Subjects With Acute Coronary SyndromeCompletedNCT03473223Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Register of Patients With haEmophilia A tReated With Afstyla®CompletedNCT04675541

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Observatory of Patients With Haemophilia B Treated by IdElvion®Active, not recruitingNCT05086575

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisCompletedNCT05130970Phase 2

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Dose Confirmation Trial of AAV5-hFIXco-PaduaCompletedNCT03489291Phase 2

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT01184846Phase 3

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Registry of Patients With Von WilLEbrand Disease Treated With Voncento®CompletedNCT04657887

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)CompletedNCT04137224Phase 2

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy VolunteersCompletedNCT04082754Phase 1

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)CompletedNCT04643587Phase 1

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney DiseaseCompletedNCT04419467Phase 2

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Effects of CSL324 in the Lung After Segmental ChallengeCompletedNCT05653713Phase 1

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult SubjectsTerminatedNCT04446000Phase 1

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited

• Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell DiseaseCompletedNCT04285827Phase 1

  Sponsor listed in the registry: CSL Behring · First submitted after CSL Behring became part of CSL Limited